Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus pembrolizumab in previously treated HRR-mutated or HRD-positive advanced solid tumors
2023-503831-17-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 23
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and olaparib in Nonhematologic neoplasms and cancer, sponsored by Merck & Co. Primary endpoint: Objective Response Rate. Started Aug 2023; status: completed.
02
Drugs
pembrolizumabolaparib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2023-503831-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503831-17-00.